We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ALPMY market cap is 17.17B. The company's latest EPS is JPY 9.4189 and P/E is 1.01.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 1.31T | 1.26T | 1.33T | 1.52T | 1.62T |
| Operating Income | 250.2B | 138.36B | 147.51B | 143.15B | 25.52B |
| Net Income | 195.41B | 120.59B | 124.09B | 98.71B | 17.05B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 2.32T | 2.27T | 2.33T | 2.46T | 3.57T |
| Total Liabilities | 1.03T | 887.51B | 872.09B | 948.56B | 1.97T |
| Total Equity | 1.29T | 1.39T | 1.46T | 1.51T | 1.6T |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 222B | 306.84B | 257.44B | 327.77B | 172.48B |
| Investing | -389.79B | -81.9B | -62.41B | -84.5B | -845.8B |
| Financing | 181.05B | -229.48B | -216.3B | -195.62B | 614.06B |
| Market Cap | 17.17B |
| Price to Earnings Ratio | 1.01 |
| Price to Sales Ratio | 0.01 |
| Price to Cash Ratio | 0.05 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | 4.85% |
| Shares Outstanding | 1.81B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.19 (1.99%) |
| Company Name | Astellas Pharma Inc (PK) |
| Address |
2-5-1 nihonbashi-honcho chuo, tokyo 103-8411 |
| Website | https://www.astellas.com |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
